Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02605824 · ClinicalTrials.gov registry record · Phase 4
Clinical Trial of NAC in Asthma
A Phase 4 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT02605824 is a Phase 4 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 1 participants.
The verdict
NCT02605824, a Phase 4 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
This study evaluates 20% n-acetylcystine (NAC) in the treatment of moderate-to-severe asthma that is complicated by mucus in the airway, as determined by CT imaging. The study is a crossover design, which means that half the study participants will get 20% NAC in the first 7-day treatment period and placebo in the next 7-day treatment period; and the other half will get placebo in the first 7-day treatment period and 20% NAC in the next 7-day treatment period.
Interventions
- DRUG 0.9% saline
- DRUG n-acetylcystine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-03 |
| Est. Completion | 2017-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02605824
The ClinicalTrials.gov registry entry for NCT02605824 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 0.9% saline is the first listed.
NCT02605824 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02605824 about?
NCT02605824 is a clinical study titled "Clinical Trial of NAC in Asthma". This study evaluates 20% n-acetylcystine (NAC) in the treatment of moderate-to-severe asthma that is complicated by mucus in the airway, as determined by CT imaging. The study is a crossover design, which means that half the study participants will get 20% NAC in the first 7-day treatment period and...
What is the current status of trial NCT02605824?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2016-03. Estimated completion is 2017-12.
What interventions are being tested in trial NCT02605824?
The interventions under investigation include: 0.9% saline (DRUG), n-acetylcystine (DRUG).
Who is sponsoring clinical trial NCT02605824?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.